Postmenopausal hormone replacement therapy: Endometrial and breast effects

Advances in Anatomic Pathology

Volumn 14, Issue 1, 2007, Pages 17-24

  Yeh, I Tien ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast; Endometrium; Hormone replacement therapy; Postmenopausal

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ATROPHY; BREAST; BREAST CANCER; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG MEGADOSE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; METAPLASIA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; STROKE; VEIN THROMBOSIS;

BREAST; BREAST NEOPLASMS; CARCINOMA; DRUG THERAPY, COMBINATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; PROGESTERONE;

EID: 33845968074     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31802ef00f     Document Type: Review

References (82)

1. Mainzer F. Vorschlag sur gehandlund der ausfallsercheinungen nach castration. Deutsche Medizinishche Wochenschrift. 1896;22:188.
2. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med. 2005;118(12 suppl 2):64-73.
3. Novak E. An appraisal of ovarian therapy. Endocrinology. 1922;6:599-620.
4. Allen E, Doisy E. An ovarian hormone: preliminary report on its localization, extraction and partial purificatin and anction in test animals. JAMA. 1923;31:819-821.
5. Schneider P. Prophylactic endocrine therapy in artificial menopause. Am J Obstet Gynecol. 1939;37:861-870.
6. Wilson RA. Feminine Forever. New York: M. Evans and Company, Inc; 1966.
7. Jones M. Women on the Verge of HRT. London: Samuel French Ltd; 1991.
8. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293:1164-1167.
9. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167-1170.
10. The Coronary Drug Project. Initial findings leading to modification of its research protocol. JAMA. 1970;214:1303-1313.
11. Group TCDPR. The Coronary Drug Project Group: findings leading to discontinuation of the 2.5mg estrogen group. JAMA. 1973;226:652-657.
12. Wilken-Jensen C, Ottesen B. The aging woman: the role of medical therapy. Int J Gynaecol Obstet. 2003;82:381-391.
13. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545-553.
14. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
16. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065-1079.
17. Campagnoli C, Ambroggio S, Biglia N, et al. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol. 1999;13(suppl 6):13-19.
18. Pickar JH, Yeh IT, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril. 2003;80:1234-1240.
19. Pickar JH, Yeh I, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;76:25-31.
20. Deligdisch L. Effects of hormone therapy on the endometrium. Mod Pathol. 1993;6:94-106.
21. Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000;13:285-294.
22. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.J Am Med Assoc. 1996;275:370-375.
23. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985;313:969-972.
24. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet and Gynecol. 1995;85:304-313.
25. Horn LC, Dietel M, Einenkel J. Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis. Eur J Obstet Gynecol Reprod Biol. 2005;122:4-12.
26. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol. 2001;54:435-440.
27. Orvieto R, Bar-Hava I, Dicker D, et al. Endometrial polyps during menopause: characterization and significance. Acta Obstet Gynecol Scand. 1999;78:883-886.
28. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361:1810-1812.
29. Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575-580.
30. Mazur MT. Endometrial hyperplasia/adenocarcinoma. A conventional approach. Ann Diagn Pathol. 2005;9:174-181.
31. Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG. 2000;107:1392-1400.
32. Schiff I, Sela HK, Cramer D, et al. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril. 1982;37:79-82.
33. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
34. Grady D, Applegate W, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19:314-335.
35. Lax SF, Kurman RJ, Pizer ES, et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24:1201-1208.
36. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814-824.
37. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch: Int J Pathol. 2004;444:213-223.
38. Horn LC, Schnurrbusch U, Bilek K, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14:348-353.
39. Russo J, Russo IH. Development of the human breast. Maturitas. 2004;49:2-15.
40. Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia. 2004;9:3-13.
41. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4:197-201.
42. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 2001;8:47-61.
43. Cline JM, Soderqvist G, Register TC, et al. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol. 2001;29:84-90.
44. Haslam SZ, Osuch JR, Raafat AM, et al. Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J Mammary Gland Biol Neoplasia. 2002;7:93-105.
45. Tavassoli FA. The influence of endogenous and exogenous reproductive hormones on the mammary glands with emphasis on experimental studies in rhesus monkeys. Verh Dtsch Ges Pathol. 1997;81:514-520.
46. Cavailles V, Gompel A, Portois MC, et al. Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J Mol Endocrinol. 2002;28:165-175.
47. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84:4559-4565.
48. Soderqvist G. Effects of sex steroids on proliferation in normal mammary tissue. Ann Med. 1998;30:511-524.
49. Marugg RC, van der Mooren MJ, Hendriks JH, et al. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur Radiol. 1997;7:749-755.
50. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med. 2003;138:168-175.
51. Rutter CM, Mandelson MT, Laya MB, et al. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA. 2001;285:171-176.
52. Hargreaves DF, Knox F, Swindell R, et al. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br J Cancer. 1998;78:945-949.
53. Lavrovskaya E, Blankenship J, Otto P, et al. The effect of hormone replacement therapy on breast epithelial proliferation and estrogen/ progesterone receptors in post-menopausal women. [abstract]. AJCP. 2005;124:651-652.
54. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
55. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92:2049-2058.
56. Campagnoli C, Abba C, Ambroggio S, et al. Breast cancer and hormone replacement therapy: putting the risk into perspective. Gynecol Endocrinol. 2001;15(suppl 6):53-60.
57. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543-1551.
58. Gertig DM, Fletcher AS, English DR, et al. Hormone therapy and breast cancer: what factors modify the association? Menopause. 2006;13:178-184.
59. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006;166:1027-1032.
60. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
61. Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise-was it inevitable? Climacteric. 2002;5:317-325.
62. Brincat M, Muscat Baron Y, Ciantar E. Hormone replacement in women with breast cancer: the HABITS study. Endocrine. 2004;24:255-257.
63. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20:2052-2060.
64. Biglia N, Sgro L, Defabiani E, et al. The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol. 2005;31:467-472.
65. Li CI, Anderson BO, Daling JR, et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2002;75:259-268.
66. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002;95:2455-2464.
67. Newcomer LM, Newcomb PA, Potter JD, et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control. 2003;14:225-233.
68. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:593-600.
69. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
70. Li CI, Daling JR, Malone KE, et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:946-954.
71. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer. 2004;100:2328-2337.
72. Li CI, Anderson BO, Daling JR, et al. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289:1421-1424.
73. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer. A clinician's view. Maturitas. 2004;49:51-57.
74. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
75. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291:1610-1620.
76. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057-2071.
77. Carroll DG. Nonhormonal therapies for hot flashes in menopause. Am Fam Physician. 2006;73:457-464.
78. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005;51:21-28.
79. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13:340-367; quiz 68-69.
80. Ettinger B, Barrett-Connor E, Hoq LA, et al. When is it appropriate to prescribe postmenopausal hormone therapy? Menopause. 2006;13:404-410.
81. North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11(6 Pt 1):589-600.
82. Executive summary. Hormone therapy. Obstet Gynecol. 2004;104(4 suppl):1S-4S.